C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more
C4 Therapeutics Inc (CCCC) - Total Assets
Latest total assets as of December 2025: $359.07 Million USD
Based on the latest financial reports, C4 Therapeutics Inc (CCCC) holds total assets worth $359.07 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
C4 Therapeutics Inc - Total Assets Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
C4 Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
C4 Therapeutics Inc's total assets of $359.07 Million consist of 71.9% current assets and 28.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.8% |
| Accounts Receivable | $2.40 Million | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: C4 Therapeutics Inc's current assets represent 71.9% of total assets in 2025, a decrease from 84.3% in 2018.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, down from 24.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.7% of total assets.
C4 Therapeutics Inc Competitors by Total Assets
Key competitors of C4 Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
C4 Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - C4 Therapeutics Inc generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - C4 Therapeutics Inc is currently not profitable relative to its asset base.
C4 Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.81 | 5.71 | 8.55 |
| Quick Ratio | 7.81 | 5.71 | 8.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $225.08 Million | $ 212.59 Million | $ 284.36 Million |
C4 Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between C4 Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.16 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | 2.7% |
| Total Assets | $359.07 Million |
| Market Capitalization | $184.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values C4 Therapeutics Inc's assets below their book value (0.51 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: C4 Therapeutics Inc's assets grew by 2.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for C4 Therapeutics Inc (2018–2025)
The table below shows the annual total assets of C4 Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $359.07 Million | +2.71% |
| 2024-12-31 | $349.60 Million | -7.13% |
| 2023-12-31 | $376.45 Million | -12.62% |
| 2022-12-31 | $430.84 Million | -14.98% |
| 2021-12-31 | $506.76 Million | +26.65% |
| 2020-12-31 | $400.14 Million | +238.35% |
| 2019-12-31 | $118.26 Million | -19.27% |
| 2018-12-31 | $146.49 Million | -- |